TRADING UPDATES: Arecor inks Eli Lilly deal; RBG appoints McNair CFO
29th Nov 2023 14:28
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it received a "milestone payment" from an unnamed pharmaceutical partner following the first commercial sale of its AT220 product. Chief Executive Officer Sarah Howell says: "The commercialisation of this product in Europe, the first to be launched incorporating our Arestat technology, is a significant milestone for Arecor and further demonstrates the strength of our Arestat platform and the value it can bring to our partners and ultimately patients." Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Monday said that it has increased the number of subjects for its ongoing Phase One clinical trial of its ultra-rapid, ultra-concentrated insulin candidate, AT278. Read More
Oxford Technology 2 VCT PLC - venture capital trust investing in quoted and unquoted technology companies - Net asset value of OT1 shares falls by 16% to 37.9 pence on August 31 from 45.3p on February 28. Similarly, NAV of OT2 shares falls to 20.5p from 25.1p, of OT3 shares to 23.6p from 33.7p, and of OT4 shares to 25.4p from 29.7p. No dividends are paid during the half year, nor are any shares bought back. Read More
(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Monday reported that its subsidiary Tetris Pharma Ltd has established an exclusive commercialisation agreement with Goodlife, a Dutch healthcare company. Read More
(Alliance News) - Arecor Therapeutics PLC on Thursday said it has signed an agreement with an unnamed "top 10 pharmaceutical company." Read More
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Announces "strong" progress across its business in the first half of 2023 amid progress for its in-house and partnered programmes. Cash as at June 30 falls 36% to GBP8.2 million from GBP12.8 million at December 31. Hails continued roll-out of Ogluo, a glucagon prefilled autoinjector pen used as a treatment for severe hypoglycaemia in children and adults living with diabetes. Glucagon is a hormone that stimulates glucose production in the liver. Arecor expects a second phase I clinical trial on diabetes 2-focused insulin candidate AT278 to complete in the fourth quarter of 2023. Read More
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Enters into an agreement with a "leading biopharmaceutical company" to support the ongoing development of a biosimilar product. Says this revenue-generating collaboration follows an earlier technology partnership between the two companies, utilising Arecor's proprietary technology platform, Arestat, and formulation expertise. Read More
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Arecor is awarded key patents in the EU and China protecting the novel formulations of its proprietary Arestat insulin products, AT278 and AT247. The European Patent Office awards patent EP3518892, while China National Intellectual Property Administration grants patent CN110582285. Firm's patent portfolio now comprises 36 patent families, with over 75 granted patents in Europe, the US and other key territories. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Posts total income of GBP3.5 million for 2022, up from GBP1.8 million in 2021. This includes revenue of GBP2.4 million, up from GBP1.2 million. Pretax loss widens to GBP10.5 million from GBP6.9 million. Research & Development costs increase to GBP8.6 million from GBP5.4 million a year earlier. Sales, General & Administrative costs also rise to GBP5.5 million from GBP2.9 million. Looking forward, 2023 will build on the solid platform produced in 2022 and will be "a year of accelerated delivery across the key areas of our business". Read More
(Alliance News) - Arecor Therapeutics PLC on Thursday celebrated several patent wins in the US and India, as it looks to strengthen its portfolio of pharmaceutical products. Read More
(Alliance News) - Arecor Therapeutics PLC on Tuesday said that it has signed an additional formulation study agreement with its top five global pharmaceutical partner, building on a collaboration formed in 2022. Read More